The important issue is can AMRI return to profitability in Yr2011? With the anticipated growth in contract rev. from overseas and cost reduction, if the co. is NOT HIDING anything ugly from the public, it's likely to achieve this eventhough there's no guidance at this time.
I wonder if someone has questioned the management for its continued slide in contract revenue in the US. They can't depend on Allegra to survive indefinitely.